[go: up one dir, main page]

MX2018010395A - Formulaciones topicas que contienen cliclosporina y usos de las mismas. - Google Patents

Formulaciones topicas que contienen cliclosporina y usos de las mismas.

Info

Publication number
MX2018010395A
MX2018010395A MX2018010395A MX2018010395A MX2018010395A MX 2018010395 A MX2018010395 A MX 2018010395A MX 2018010395 A MX2018010395 A MX 2018010395A MX 2018010395 A MX2018010395 A MX 2018010395A MX 2018010395 A MX2018010395 A MX 2018010395A
Authority
MX
Mexico
Prior art keywords
cliclosporine
formulations containing
same
formulations
topical formulations
Prior art date
Application number
MX2018010395A
Other languages
English (en)
Inventor
K Mitra Ashim
L Weiss Sidney
J Mcnally Eugene
Original Assignee
Sun Pharma Global Fze
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59744365&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018010395(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharma Global Fze filed Critical Sun Pharma Global Fze
Publication of MX2018010395A publication Critical patent/MX2018010395A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El presente documento se proporcionan formulaciones para formulaciones oftálmicas tópicas que contienen de 0.087 a 0.093% en peso de ciclosporina, y métodos de hacer y usar tales formulaciones. En algunos aspectos y modalidades las formulaciones pueden incluir un lípido de polioxilo o ácido graso, y/o un alcohol polialcoxilado y pueden incluir nanomicelios. También se incluyen en el presente documento métodos para tratar o prevenir enfermedades o condiciones, tales como enfermedades o afecciones oculares.
MX2018010395A 2016-02-29 2017-02-28 Formulaciones topicas que contienen cliclosporina y usos de las mismas. MX2018010395A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662301576P 2016-02-29 2016-02-29
US201662302058P 2016-03-01 2016-03-01
US201662302730P 2016-03-02 2016-03-02
US201662311177P 2016-03-21 2016-03-21
PCT/US2017/020008 WO2017151657A1 (en) 2016-02-29 2017-02-28 Topical cyclosporine-containing formulations and uses thereof

Publications (1)

Publication Number Publication Date
MX2018010395A true MX2018010395A (es) 2018-11-29

Family

ID=59744365

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018010395A MX2018010395A (es) 2016-02-29 2017-02-28 Formulaciones topicas que contienen cliclosporina y usos de las mismas.
MX2024010721A MX2024010721A (es) 2016-02-29 2018-08-29 Formulaciones topicas que contienen ciclosporina y usos de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024010721A MX2024010721A (es) 2016-02-29 2018-08-29 Formulaciones topicas que contienen ciclosporina y usos de las mismas.

Country Status (21)

Country Link
US (4) US10918694B2 (es)
EP (2) EP4410312A3 (es)
JP (3) JP7072517B2 (es)
KR (1) KR102766771B1 (es)
CN (2) CN119185511A (es)
AU (2) AU2017227585C1 (es)
BR (1) BR112018067946A8 (es)
CA (1) CA3015626A1 (es)
DK (1) DK3423076T3 (es)
ES (1) ES2981702T3 (es)
FI (1) FI3423076T3 (es)
IL (1) IL268056A (es)
MX (2) MX2018010395A (es)
NZ (2) NZ755442A (es)
PL (1) PL3423076T3 (es)
PT (1) PT3423076T (es)
RU (1) RU2747455C2 (es)
SA (1) SA519410114B1 (es)
SG (1) SG11201906729RA (es)
WO (1) WO2017151657A1 (es)
ZA (1) ZA201904704B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2914472C (en) 2012-08-24 2019-09-03 Ashim K. Mitra Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
PT3373976T (pt) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Formulações tópicas e suas utilizações
RU2747455C2 (ru) 2016-02-29 2021-05-05 Сан Фарма Глобал Фзе Циклоспорин-содержащие лекарственные формы для наружного применения и их применения
CN112957450A (zh) * 2019-12-20 2021-06-15 艾棣维欣(苏州)生物制药有限公司 一种难溶性药物的水溶液及其制备方法
AU2022295164A1 (en) 2021-06-14 2024-01-25 Sun Pharmaceutical Industries Limited Cyclosporine formulations for use in patients undergoing cataract surgery
AU2021267217A1 (en) * 2021-08-20 2024-02-29 Sun Pharmaceutical Industries Limited Stable cyclosporine ophthalmic formulation and manufacturing process thereof
WO2024042550A1 (en) * 2022-08-25 2024-02-29 Sentiss Pharma Private Limited Ophthalmic combination composition
KR20250096644A (ko) * 2022-11-04 2025-06-27 클라리스 바이오, 인크. 크로마칼림의 국소 안구 전달
WO2024246776A1 (en) 2023-05-29 2024-12-05 Sun Pharmaceutical Industries Limited Stable cyclosporine ophthalmic formulation and manufacturing process thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0642332T3 (da) * 1992-05-13 1997-06-16 Sandoz Ltd Ophthalmiske præparater indeholdende cyclosporin
NZ247516A (en) 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5484597A (en) 1993-07-30 1996-01-16 Chesebrough-Pond's Usa Co. Clear hydroalcholic cosmetic microemulsions
NZ280689A (en) 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
MX9701946A (es) 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
US7678836B2 (en) 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US20030176356A1 (en) 2001-04-24 2003-09-18 University Of North Texas Health Science Center Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma
KR100978836B1 (ko) 2001-10-19 2010-08-30 이소테크니카 인코포레이티드 신규한 시클로스포린 유사체 미세유화액 예비농축물
WO2004069181A2 (en) 2003-02-03 2004-08-19 Pharmacia Corporation Composition for the treatment of intraocular pressure
JP2004238346A (ja) 2003-02-07 2004-08-26 Shiono Chemical Co Ltd トラニラストの安定な水溶液製剤
AU2003228126A1 (en) 2003-05-02 2004-11-23 Arturo Jimenez Bayardo Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
ATE412400T1 (de) 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
KR20080029974A (ko) 2005-06-09 2008-04-03 산텐 세이야꾸 가부시키가이샤 로플루밀라스트 점안액
NZ562109A (en) 2005-06-16 2011-03-31 Myrexis Inc Pharmaceutical compositions containing substituted (4-Phenyl)-methyl-(quinazolin-4-yl)-amine compounds, uses thereof, and methods of preparing the same
US20070015691A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
EP1904056B1 (en) 2005-07-18 2009-04-29 Minu, L.L.C. Use of a macrolide to restore corneal sensation
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
JPWO2007126110A1 (ja) 2006-04-24 2009-09-17 ナノキャリア株式会社 低分子薬物内包ポリマーミセルの製造方法
JPWO2007136134A1 (ja) 2006-05-23 2009-10-01 ナノキャリア株式会社 疎水性薬物内包ポリマーミセルの製造方法
US8147868B2 (en) 2006-07-18 2012-04-03 Nanocarrier Co., Ltd. Physiologically active polypeptide- or protein-encapsulating polymer micelles, and method for production of the same
US20100310462A1 (en) 2007-04-18 2010-12-09 Biochromix Ab Binding of pathological forms of proteins using conjugated polyelectrolytes
US8512687B2 (en) 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
WO2009028674A1 (ja) 2007-08-29 2009-03-05 Wakamoto Pharmaceutical Co., Ltd. ラタノプロスト含有水性医薬組成物
MX2007011165A (es) 2007-09-12 2009-03-11 Arturo Jimenez Bayardo Composición farmacéutica estable de timolol, dorzolamida y brimonidina.
AU2008310956B2 (en) 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
BRPI0822221A2 (pt) 2008-01-04 2015-06-23 Alcon Pharmaceuticals Ltd Composições aquosas e estáveis de ciclosporina
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
KR20160123400A (ko) 2008-05-28 2016-10-25 알콘 리서치, 리미티드 자기보존 에멀젼
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
BRPI1010175A2 (pt) 2009-06-02 2016-03-29 Keller Brian Charles "composição química que inclui um conjugado de lipídio-peg e lipossoma"
AU2010259184B2 (en) 2009-06-09 2015-08-13 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
MX2012003296A (es) 2009-09-17 2012-04-20 Senju Pharma Co Gotas oculares acuosas que contienen latanoprost, y metodo para inhibir la adsorcion de latanoprost a una resina.
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
WO2011138801A1 (en) 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd. Novel ophthalmic compositions
US20130065888A1 (en) 2011-08-15 2013-03-14 Biserka Cetina-Cizmek Ophthalmic formulations and processes for their preparation
US9278132B2 (en) 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
RU2014149993A (ru) 2012-05-11 2016-07-10 Сипла Лимитед Фармацевтическая композиция
CA2914472C (en) 2012-08-24 2019-09-03 Ashim K. Mitra Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
WO2014126997A1 (en) 2013-02-13 2014-08-21 The Research Foundation For The State University Of New York Glaucoma treatment
EA201692402A1 (ru) * 2014-05-23 2017-03-31 Окьюлар Текнолоджис Сарл Лекарственные формы для местного применения и их использование
US20150352176A1 (en) * 2014-06-06 2015-12-10 Newport Research, Inc. Oil-free and fat-free aqueous suspensions of cyclosporin
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20180133217A1 (en) 2015-05-04 2018-05-17 Ocular Technologies Sarl Topical formulations and uses thereof
PT3373976T (pt) * 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Formulações tópicas e suas utilizações
WO2017083410A1 (en) 2015-11-12 2017-05-18 Ocular Technologies Sarl Topical formulations and uses thereof
RU2747455C2 (ru) 2016-02-29 2021-05-05 Сан Фарма Глобал Фзе Циклоспорин-содержащие лекарственные формы для наружного применения и их применения
WO2017152129A2 (en) 2016-03-03 2017-09-08 Ocular Technologies Sarl Treatment of glaucoma and/or retinal diseases and formulations useful therefore

Also Published As

Publication number Publication date
CN109843316A (zh) 2019-06-04
US10918694B2 (en) 2021-02-16
JP2022110054A (ja) 2022-07-28
EP3423076B1 (en) 2024-04-17
RU2747455C2 (ru) 2021-05-05
US20210145924A1 (en) 2021-05-20
US20240197818A1 (en) 2024-06-20
ES2981702T3 (es) 2024-10-10
ZA201904704B (en) 2022-10-26
JP7547411B2 (ja) 2024-09-09
KR102766771B1 (ko) 2025-02-14
US20190060397A1 (en) 2019-02-28
JP2019507154A (ja) 2019-03-14
RU2019130403A (ru) 2021-03-26
FI3423076T3 (fi) 2024-06-24
JP2024161602A (ja) 2024-11-19
WO2017151657A1 (en) 2017-09-08
BR112018067946A2 (pt) 2019-01-15
EP4410312A2 (en) 2024-08-07
PT3423076T (pt) 2024-07-01
AU2017227585A1 (en) 2018-10-18
KR20180117661A (ko) 2018-10-29
JP7072517B2 (ja) 2022-05-20
PL3423076T3 (pl) 2024-08-19
NZ755442A (en) 2023-04-28
AU2022203135A1 (en) 2022-06-02
SA519410114B1 (ar) 2024-02-11
RU2019130403A3 (es) 2021-03-26
IL268056A (en) 2019-08-29
US20230083458A1 (en) 2023-03-16
NZ785158A (en) 2025-03-28
AU2017227585B2 (en) 2022-02-17
SG11201906729RA (en) 2019-08-27
EP3423076A1 (en) 2019-01-09
DK3423076T3 (da) 2024-07-08
AU2017227585C1 (en) 2022-05-26
AU2022203135B2 (en) 2025-09-11
BR112018067946A8 (pt) 2022-11-08
MX2024010721A (es) 2024-09-10
EP4410312A3 (en) 2024-11-20
CA3015626A1 (en) 2017-09-08
US11951153B2 (en) 2024-04-09
EP3423076A4 (en) 2019-11-27
CN119185511A (zh) 2024-12-27

Similar Documents

Publication Publication Date Title
MX2018010395A (es) Formulaciones topicas que contienen cliclosporina y usos de las mismas.
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
CL2019000586A1 (es) Composiciones de toxinas clostridiales no proteicas.
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
DOP2016000298A (es) Pirazolopiridinas y pirazolopirimidinas
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
AR102198A1 (es) Proceso para reducir partículas subvisibles en una formulación farmacéutica
CL2017001301A1 (es) Composiciones oftálmicas estabilizadas de omega 3
MX2016000405A (es) Metodos y formulaciones que permiten la modulacion de respuestas inmunitarias relacionadas con la administracion de un farmaco biofarmaceutico.
MY207914A (en) Semifluorinated alkane compositions comprising omega-3 fatty acid ethyl esters
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MX2024012898A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas
CY1124538T1 (el) Χρηση prg4 για τη βελτιωση της δυναμικης οπτικης οξυτητας και εκτροπων υψηλοτερης ταξης
BR112017007428A2 (pt) composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença
MX385698B (es) Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
MX2021007161A (es) Agente que contiene acido ursodesoxicolico para tratar o prevenir la presbicia.
CL2020002519A1 (es) Composiciones de erenumab y usos de las mismas
EP4364810A3 (en) Topical formulations and uses thereof
MY194044A (en) Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore